Prenetics Q2 Revenue Soars 288% YoY, Raises FY26 Guidance, Achieves First Positive Adjusted FCF
PRE has more than doubled off its 52-week low of $7.175.
Summary
Prenetics reported Q2 2026 revenue of $46.5M, up 288% YoY, raised FY2026 guidance to $220-230M, and achieved its first positive Adjusted Free Cash Flow month in July. The company initiated FY2027 IM8 revenue guidance of $400M+.
Key Events · Earnings and Guidance · PRE
-
Q2 Revenue Up 288% YoY
Total revenue of $46.5M, within guidance of $46-48M. IM8 revenue of $45.0M, up ~359% YoY, marking the sixth consecutive record quarter.
-
First Positive Adjusted FCF
Consolidated Adjusted Free Cash Flow turned positive in July 2026, the first month in company history, and is expected to remain positive for Q3 and beyond.
-
FY26 Guidance Raised
Full-year total revenue guidance raised to $220-230M (from $210-220M), with IM8 contributing $215-222M. Q3 guidance set at $63-64M total revenue.
-
FY27 IM8 Guidance Initiated
Company initiated FY2027 IM8 revenue guidance of $400M or more, with no contribution from upcoming product launches assumed.
Analysis · PRE · Life Sciences
Prenetics delivered a blowout quarter with IM8 revenue up 359% YoY, raised full-year guidance, and hit a critical inflection point: consolidated Adjusted Free Cash Flow turned positive in July for the first time in company history. The company also initiated FY2027 IM8 revenue guidance of $400M+, signaling management's confidence in sustained hypergrowth. The $1B General Catalyst facility is already showing its impact, funding customer acquisition while the company's own cash flow turns positive. This is a major positive development for a company that was burning cash just a quarter ago.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 37.1% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRE was trading at $19.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $332.1M. The 52-week trading range was $7.18 to $23.63. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.